MedPath

BAYER AUSTRALIA LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:0
Completed:6

Trial Phases

2 Phases

Phase 2:2
Phase 3:4

Drug Approvals

237

TGA:231
NMPA:6

Drug Approvals

Drospirenone and EthinylEstradiol tablets (Ⅱ)

Product Name
屈螺酮炔雌醇片(Ⅱ)
Approval Number
国药准字HJ20140972
Approval Date
Oct 30, 2023
NMPA

Drospirenone and Ethinylestradiol Tablets

Product Name
优思明
Approval Number
国药准字HJ20170316
Approval Date
Mar 21, 2022
NMPA

Drospirenone and Ethinylestradiol Tablets

Product Name
优思明
Approval Number
国药准字HJ20170317
Approval Date
Mar 21, 2022
NMPA

Loratadine Syrup

Product Name
开瑞坦
Approval Number
国药准字HJ20170182
Approval Date
Jan 24, 2022
NMPA

Drospirenone and EthinylEstradiol tablets(Ⅱ)

Product Name
屈螺酮炔雌醇片(Ⅱ)
Approval Number
H20140972
Approval Date
May 31, 2019
NMPA

Aflibercept Intravitreous Injection

Product Name
艾力雅
Approval Number
S20180001
Approval Date
Feb 2, 2018
NMPA

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (66.7%)
Phase 2
2 (33.3%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.